Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms, Glandular and Epithelial 2Carcinoma 2Uterine Cervical Dysplasia 1Urogenital Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms 1Neoplasm Metastasis 1Gonadal Disorders 1Genital Neoplasms, Female 1Genital Diseases, Female 1Female Urogenital Diseases and Pregnancy Complications 1Female Urogenital Diseases 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Adnexal Diseases 1

Interventions

Carboplatin 3Bevacizumab 3olaparib 2niraparib 2anlotinib 2Paclitaxel 2Diet, Mediterranean 2Blood Specimen Collection 2temsirolimus 1relacorilant 1pembrolizumab 1nintedanib 1liposomal doxorubicin 1lenvatinib 1entinostat 1avelumab 1Trabectedin 1Tissue Banks 1Papanicolaou Test 1Ocoxin 1NUC-1031 1Gemcitabine 1Food, Formulated 1Filgrastim 1Diffusion 1Dexamethasone 1Cell Count 1CP protocol 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Diseases × Ocoxin × Gynecologic × Clear all
NCT03562897 2022-07-06

Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer

Catalysis SL

Phase 2 Completed
40 enrolled
Gynecologic

Adnexal Diseases, Carcinoma, Endocrine System Diseases, Endocrine Gland Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Female, Genital Neoplasms, Female, Gonadal Disorders, Neoplasm Metastasis, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms, Female Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡